The Danish company developed the most lucrative new drug the world has ever seen. Then America’s Eli Lilly outmaneuvered it ...
After a year at the helm, Novo Nordisk's CEO Maziar Mike Doustdar's task of closing the gap to pacesetter Eli Lilly doesn't ...
By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and ...
Novo Nordisk Q2 results: obesity drug growth (Wegovy pill) offsets pricing pressure. Shares fell 6%, but DCF suggests 25% ...
1don MSN
Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame
The Danish drugmaker also revealed an improved outlook for the year.
Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street ...
Novo Nordisk CEO Mike Doustdar faces investors and analysts on Wednesday under pressure to restore confidence in the drugmaker's longer-term growth prospects after an upgraded 2026 outlook failed to ...
The Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline ...
CNBC's Annika Kim Constantino reports on news regarding Novo Nordisk.
Novo Nordisk won a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. from the District Court of The Hague in a patent infringement case involving a compounded semaglutide nasal sprayThe ...
Novo Nordisk shares plunged on Friday, erasing more than $30 billion in market value after the Danish drugmaker said a ...
Novo Nordisk raises 2025 outlook again on strong GLP-1 sales as Ozempic/Wegovy grow and oral Wegovy surges—get key Q2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results